WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative dialysis products manufacturer serving the healthcare industry, announced today that the process to electronically exercise its new warrants (Nasdaq: RMTIZ) has been activated at Depository Trust Corporation (DTC).

Warrant holders may now contact their brokerage firm to initiate warrant exercises electronically via DTC. Holders of paper certificates may also exercise their warrants by submission directly to the transfer agent as noted on the reverse side of the warrant certificate.

Warrant holders of the new warrants may exercise those warrants which permit the purchase of one common share for $3.90. The new warrant (Cusip no. 774374-12-8) is traded on the Nasdaq Exchange under the trading symbol RMTIZ. Unless earlier exercised, the new warrant (Nasdaq:RMTIZ) will expire on January 26, 2006.

Rockwell common shares closed at $4.57 yesterday.

Questions regarding the warrants can be directed to American Stock Transfer and Trust at their customer service line, 800-937-5449.

(return to News Index) Wednesday, December 6, 2005

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative dialysis products manufacturer serving the healthcare industry, announced today that it completed its warrant exchange offer.

Warrant holders exchanged 3,270,303 warrants, or approximately 90% of the old warrants. The new warrant (Cusip no. 774374-12-8) is traded on the Nasdaq Exchange under the symbol RMTIZ (Nasdaq:RMTIZ).

Both the old warrant (Nasdaq: RMTIW) and the new warrant (Nasdaq:RMTIZ) will expire on January 26, 2006.

The new warrants have an exercise price of $3.90 per Common Share. Rockwell expects it could raise gross proceeds of approximately $12,750,000 if all of the new warrants are exercised by their expiration on January 26, 2006.

Rockwell intends to use the majority of any net proceeds to obtain FDA approval for its proprietary iron-delivery product. If Rockwell obtains FDA approval, Rockwell expects its proprietary iron-delivery product to compete for the estimated $300,000,000 U.S. market for iron therapy for dialysis patients.

Rockwell also anticipates using a portion of any proceeds for the expansion of its business including additional working capital and may include expansion of its production and distribution network.

Rockwell reported sales growth of 61% and earnings per share of $.04 in the first three quarters of 2005.

Rockwell Medical Technologies, Inc. is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products that improve the quality of care for dialysis patients. Dialysis is a process that duplicates kidney function for those patients whose kidneys have failed to work properly and suffer from chronic kidney failure, a condition also known as end stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has experienced an average annual increase of approximately 6%-8% over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the proprietary Dri-Sate® Dry Acid Concentrate Mixing System, RenalPure® Liquid Acid Concentrate, SteriLyte® Liquid Bicarbonate Concentrate, RenalPure® Powder Bicarbonate Concentrate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items. Rockwell is currently in the process of developing and gaining FDA approval of a proprietary iron-delivery product which will be administered to dialysis patients via dialysate.

Certain statements in this press release constitute "forward-looking statements". These statements include statements regarding the amount of expected proceeds from the exercise of warrants, the use of those proceeds, and Rockwell's expectations with respect to its iron-delivery product. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, the market price of Rockwell's common shares not exceeding the exercise price of the new warrants, the failure of warrant holders to exercise their warrants, the failure of Rockwell to obtain FDA approval of its iron-delivery product, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports and registrations statements filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

(return to News Index) Thursday, November 17, 2005

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis products manufacturer serving the healthcare industry, reported today that it has formed a Scientific Advisory Board (SAB) to advise the Company on its clinical development and market preparation for its proprietary iron-delivery product, Soluble Ferric Pyrophosphate. The SAB consists of experts in the fields of renal anemia, iron therapy, nephrology and FDA regulatory approval. The SAB's role is to provide direction and guidance as the product moves through the FDA approval process.

The SAB is comprised of

• Anatole Besarab, MD, Director of Clinical Research, Division of Nephrology and Senior Staff Physician, Henry Ford Hospital, Detroit
• Rajiv Agarwal, MD, Associate Professor of Medicine,Indiana University School of Medicine, Indianapolis
• Ajay Gupta, MD, Associate Professor of Medicine,Division of Nephrology, UCLA and Drew University Schools of Medicine, Los Angeles
• Bert Spilker, PhD, MD,President Bert Spilker & Associates, LLC
• Nancy Chew, M.S.,RAC President, Regulatory Affairs, North America LLC

Mr. Robert L. Chioini, Chairman, CEO and President of Rockwell stated, “We have assembled an extraordinary group of world-class nephrologists and clinicians who are leaders in the area of renal anemia and iron therapy to advise us as we advance through our Phase III development program for our proprietary iron-delivery product. The SAB will play an important role in the achievement of both short- and long-term objectives for our Soluble Ferric Pyrophosphate development. We are extremely pleased that such brilliant individuals have joined us in our efforts to develop and commercialize this revolutionary iron-delivery product.”

Rockwell Medical Technologies, Inc. is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products that improve the quality of care for dialysis patients. Dialysis is a process that duplicates kidney function for those patients whose kidneys have failed to work properly and suffer from chronic kidney failure, a condition also known as end stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the proprietary Dri-Sate® Dry Acid Concentrate Mixing System, RenalPure® Liquid Acid Concentrate, SteriLyte® Liquid Bicarbonate Concentrate, RenalPure® Powder Bicarbonate Concentrate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release with respect to Rockwell's anticipated sales revenue or possible proceeds from financing constitute "forward-looking statements". These statements include statements regarding the amount of expected proceeds from the exercise of warrants, the use of those proceeds and the performance of Rockwell's iron-delivery product. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.
(return to News Index) Tuesday November 8, 2005

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis products manufacturer in the healthcare sector, reported its third quarter results today. Sales increased 75% and Earnings per Share doubled to $.02 from the third quarter last year. Nine Month revenues were up 61% and nine month net income increased 75% for the first nine months of 2005 compared to the same period in 2004.

HIGHLIGHTS

Third Quarter 2005

• Record quarterly revenues of $7,828,262.
• Sales increased 75% over the third quarter of 2004.
• Gross Profit Margins improved 1.9% sequentially over the second quarter of 2005.
• Net Income increased 139% to $156,177 over the third quarter last year.
• Sequentially, net income increased 83% to $70,721 over the second quarter of 2005.
• Earnings per Share doubled to $.02 from $.01 last year and last quarter.

• Revenues increased 61% to $21,238,803 over first nine months of 2004.
• Net Profit increased 75% to $350,848 over the first nine months of 2004.
• Earnings per Share was $.04, double the result from the first nine months of 2004.

Mr. Robert L. Chioini, Chairman and Chief Executive Officer of Rockwell Medical Technologies, Inc. stated, “Overall, we are pleased with our third quarter results which demonstrated strong growth in our sales as well as improvement in our gross profit margins and net earnings. We have begun to accelerate our efforts and our funding to gain FDA approval for our iron-delivery product so we are pleased to see improved earnings while making these important investments.”

Rockwell will be hosting a conference call to review its third quarter results on Tuesday, November 8, 2005 at 11:00 am EDT. Investors are encouraged to call in five minutes in advance of the call at 888-896-0862 or may listen on the web at: http://orion.calleci.com/servlet/estreamgetevent?id=6084&folder=default using Windows Media Player. See www.rockwellmed.com for more details and playback options.

Rockwell Medical Technologies, Inc. is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products that improve the quality of care for dialysis patients. Dialysis is a process that duplicates kidney function for those patients whose kidneys have failed to work properly and suffer from chronic kidney failure, a condition also known as end stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased approximately 6-8% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the proprietary Dri-Sate® Dry Acid Concentrate Mixing System, RenalPure® Liquid Acid Concentrate, SteriLyte® Liquid Bicarbonate Concentrate, RenalPure® Powder Bicarbonate Concentrate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items
Certain statements in this press release with respect to Rockwell's anticipated sales revenue constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors, failure to obtain FDA approval, and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., announced today that it will hold a conference call on Tuesday, November 8, 2005 at 11:00AM EST to discuss its third quarter 2005 results. The Company intends to release its results before the market opens on the same date. Robert Chioini, Chairman and CEO, and Thomas Klema, CFO, will be hosting the call to review Rockwell's results and answer questions from investors.

The call will be held on:

Tuesday, November 8, 2005
Starting Time 11:00AM Eastern Time
Dial in Number: 888-896-0862

When calling in please refer to the Rockwell Medical Technologies, Third Quarter Conference Call and provide the operator with your name and company affiliation.

Investors who prefer to participate using the internet may access the following link for Real Player:
http://orion.calleci.com/servlet/estreamgetevent?id=6082&folder=default

Or for Windows Media Player:
http://orion.calleci.com/servlet/estreamgetevent?id=6084&folder=default

International Investors may dial in directly on 973-935-8597

Investors who are unable to listen to the Rockwell earnings conference call will be able to access a replay via our web site at www.rockwellmed.com. There will be no telephone replay.


We appreciate your interest in Rockwell.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a dialysis products manufacturer serving the healthcare industry, reported today that the U.S. Securities and Exchange Commission (SEC) has declared effective Rockwell's registration statement relating to its warrant exchange offer.

Under the terms of the exchange offer, each of Rockwell's current outstanding publicly traded common share purchase warrants (Nasdaq: RMTIW) with an exercise price of $4.50 can be exchanged for a new common share purchase warrant with an exercise price of $3.90. The exchange offer expires at 5:00 pm (EST), November 28, 2005. Both old and new warrants will expire on January 26, 2006. Rockwell currently has 3,625,000 outstanding publicly traded common share purchase warrants.

Rockwell expects it could raise more than $13,800,000 if all the old warrants are exchanged for new warrants and subsequently all of the new warrants are exercised by the warrant holders. Rockwell intends to use a portion of the proceeds raised from the warrant exercise for business expansion including additional production facilities, and intends to utilize the majority of the proceeds to obtain FDA approval for its proprietary iron-delivery product. As demonstrated during Phase II clinical trials, and compared to the current IV iron delivery method, Rockwell's iron-delivery product provides a safer, more effective and less costly delivery of iron to the dialysis patient. Iron supplementation is vital to achieve adequate therapeutic response to expensive anemia treatments received by 90% of all dialysis patients. Upon FDA approval, Rockwell expects its proprietary iron-delivery product to aggressively compete in the $300,000,000 U.S. iron market as well as the $500,000,000-plus global iron market.

Mr. Robert L. Chioini, Chairman, CEO and President of Rockwell stated, “We are at an important stage in the development of our proprietary iron-delivery product and the capital raised from this exchange offer will be used primarily to accelerate that initiative and gain FDA market approval. We have separate studies that we anticipate will begin in both the fourth quarter of this year and the first quarter of 2006 and we will keep our shareholders apprised of our progress.” Mr. Chioini further stated, “We are operating in a changing, dynamic marketplace and we will use our resources to capitalize on opportunities, including growing our core concentrate business as well as entering markets such as our iron drug-delivery product.”

The terms of the exchange offer are set forth in a prospectus to be provided to current warrant holders and can be accessed via the internet at:
http://www.sec.gov/Archives/edgar/data/1041024/000095012405005787/0000950124-05-005787.txt

Rockwell Medical Technologies, Inc. is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products that improve the quality of care for dialysis patients. process that duplicates kidney function for those patients whose kidneys have Dialysis is a process that duplicates kidney function for those patients whose kidneys have failed to work properly and suffer from chronic kidney failure, a condition also known as end stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has experienced an average annual increase of approximately 6%-8% over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the proprietary Dri-Sate® Dry Acid Concentrate Mixing System, RenalPure® Liquid Acid Concentrate, SteriLyte® Liquid Bicarbonate Concentrate, RenalPure® Powder Bicarbonate Concentrate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items. Rockwell is currently in the process of developing and gaining FDA approval of a proprietary iron-delivery product which will be administered to dialysis patients via dialysate.

Certain statements in this press release with respect to Rockwell's business and operations, including the statements regarding the Company's anticipated sales revenue and gross profit margins constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis products manufacturer serving the healthcare industry, reported today that it has signed a concentrate supply agreement with Fletcher Allen Health Care Renal Services.

The exclusive supply agreement calls for Fletcher Allen to purchase Rockwell's RenalPure® Liquid Acid Concentrate and SteriLyte® Liquid Bicarbonate, as well as its dialyzer reuse solution needed for cleaning artificial kidneys. The contract is for a term of two years, after which it may be extended annually upon mutual agreement of both parties. Rockwell will deliver product in bulk to distributor McKesson Medical-Surgical Maine, Inc., located in the Northeast United States. McKesson Medical is also under contract with Rockwell to deliver product directly to Fletcher Allen. Rockwell anticipates that the Fletcher Allen Supply Agreement will generate sales revenue in excess of $500,000 annually.

Fletcher Allen Health Care Renal Services provides hemodialysis and peritoneal dialysis therapy for patients with end-stage renal disease in six dialysis centers in Vermont and upstate New York.

Mr. Robert L. Chioini, Chairman, CEO and President of Rockwell stated, “We are pleased to be able to provide our concentrate and dialyzer reuse products to Fletcher Allen. The structure of this supply agreement enables us to increase our sales and expand our presence in the Northeast with a very cost effective method.”

Rockwell Medical Technologies, Inc. is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products that improve the quality of care for dialysis patients. Dialysis is a process that duplicates kidney function for those patients whose kidneys have failed to work properly and suffer from chronic kidney failure, a condition also known as end stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the proprietary Dri-Sate® Dry Acid Concentrate Mixing System, RenalPure® Liquid Acid Concentrate, SteriLyte® Liquid Bicarbonate Concentrate, RenalPure® Powder Bicarbonate Concentrate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release with respect to Rockwell's anticipated sales revenue or possible proceeds from financing constitute "forward-looking statements". These statements include statements regarding the amount of expected proceeds from the exercise of warrants, the use of those proceeds and the performance of Rockwell's iron-delivery product. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis products manufacturer serving the healthcare industry, reported today that it has renegotiated and renewed its lease for its manufacturing facility in Grapevine, Texas.

The lease renewal runs until August 31, 2010 and is expected to save Rockwell approximately $250,000 over the five-year term, as compared to its initial five-year lease. Located near Dallas, this manufacturing facility is approximately 51,100 square feet and has been in operation since 2001. Rockwell supplies dialysis clinics throughout the South Central Region of the United States from the Texas facility.

“This lease renewal is consistent with our goal to reduce our operating costs and increase our productivity. In addition, we are implementing capital projects in the second half of 2005 that we believe will contribute to increasing our productivity and lowering our unit costs in certain areas,” stated Thomas E. Klema, Vice President and Chief Financial Officer.

Rockwell Medical Technologies, Inc. announced on August 10, 2005, that its second quarter sales increased 77.8% over the second quarter of 2005 and that its six month sales had increased over 54% from last year.

Rockwell Medical Technologies, Inc. is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products that improve the quality of care for dialysis patients. Dialysis is a process that duplicates kidney function for those patients whose kidneys have failed to work properly and suffer from chronic kidney failure, a condition also known as end stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the proprietary Dri-Sate® Dry Acid Mixing System, RenalPure™ Liquid Acid, RenalPure™ Powder Bicarbonate, SteriLyte® Liquid Bicarbonate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release with respect to Rockwell's business and operations, including the statements regarding the Company's anticipated sales revenue and gross profit margins constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors, failure to obtain FDA approval, and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis products manufacturer serving the healthcare industry, announced today that Robert L. Chioini, Rockwell's CEO, was named a winner by professional services firm Ernst & Young LLP for the Ernst & Young Entrepreneur of The Year® 2005 Awards for the Central Great Lakes region in the Emerging Companies category. Mr. Chioini was selected from 30 finalists in Eastern Michigan and Northwestern Ohio by an independent panel of judges comprised of local business, academic and community leaders and announced as an award recipient at an awards banquet in June 2005 at the Ritz-Carlton in Dearborn, Michigan.

Mr. Chioini will be eligible for consideration for the Entrepreneur of The Year 2005 national program. Winners in several national categories, as well as the overall national Ernst & Young Entrepreneur of The Year, will be announced at the annual awards gala in Palm Springs, Calif. on November 19, 2005

About The Ernst & Young Entrepreneur Of The Year® Program; The Ernst & Young Entrepreneur of The Year Program was created and is produced by professional services firm Ernst & Young LLP. As the first award of its kind, Ernst & Young Entrepreneur of The Year recognizes outstanding entrepreneurs who are building and leading dynamic and growing businesses. The program honors entrepreneurs through regional, national and global award programs in over 100 cities and 35 countries.

Rockwell reported last week that its second quarter 2005 revenue increased 78% over the second quarter of last year and that its year to date revenue was up 54% over the first half of 2004.

About Ernst & Young; Ernst & Young, a global leader in professional services, is committed to restoring the public's trust in professional services firms and in the quality of financial reporting. Its 100,000 people in 140 countries around the globe pursue the highest levels of integrity, quality, and professionalism to provide clients with solutions based on financial, transactional, and risk-management knowledge in Ernst & Young's core services of Audit, Tax, and Transaction Advisory Services. Ernst & Young practices also provide legal services in some parts of the world where permitted. Further information about Ernst & Young and its approach to a variety of business issues can be found at www.ey.com/perspectives. Ernst & Young refers to all the members of the global Ernst & Young organization.

Rockwell Medical Technologies, Inc. is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products that improve the quality of care for dialysis patients. Dialysis is a process that duplicates kidney function for those patients whose kidneys have failed to work properly and suffer from chronic kidney failure, a condition also known as end stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the proprietary Dri-Sate® Dry Acid Mixing System, RenalPure™ Liquid Acid, RenalPure™ Powder Bicarbonate, SteriLyte® Liquid Bicarbonate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, reported today that it received notice from the European Patent and Trademark Office that it has allowed claims and will be issuing a patent for Rockwell's proprietary iron delivery product. The European Patent and Trademark Office will issue the patent for “Method and Pharmaceutical Composition for Iron Delivery in Hemodialysis and Peritoneal Dialysis Patients”.

The countries the European patent is expected to cover are Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, the Netherlands, Portugal, Spain, Sweden, Switzerland and the United Kingdom.

Mr. Rob Chioini, Chairman, CEO and President of Rockwell stated, “This patent approval in the European Union is a significant step for protecting our proprietary iron delivery technology.”

Rockwell Medical Technologies, Inc. is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products that improve the quality of care for dialysis patients. Dialysis is a process that duplicates kidney function for those patients whose kidneys have failed to work properly and suffer from chronic kidney failure, a condition also known as end stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the proprietary Dri-Sate® Dry Acid Mixing System, RenalPure™ Liquid Acid, RenalPure™ Powder Bicarbonate, SteriLyte® Liquid Bicarbonate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release with respect to Rockwell's business and operations, including the statements regarding the Company's anticipated sales revenue and gross profit margins constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors, failure to obtain FDA approval, and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc. a leading, innovative hemodialysis products manufacturer in the healthcare sector, reported its second quarter results today. Sales increased 77.8% over the second quarter last year. First half 2005 revenues were up 54.3% over last year. Net Income in the second quarter of 2005 was $85,456 or $.01 per share.

HIGHLIGHTS:

Second Quarter 2005

• Record quarterly revenues of $7,791,033.
• Salesincreased 77.8% over the second quarter of 2004.
• Salesrevenue was up 38.6% sequentially over the first quarter of 2005.
• Concentrateproduct line revenue increased 50% over the second quarter of 2004.
• NetIncome was $85,456
• Earningsper Share was $.01

• First half2005 revenues of $13,410,541.
• First half2005 revenues increased 54.3% over the first half of 2004.
• First halfprofits of $194,672 increased 44% over first half 2004.
• Earnings perShare was $.02.
• Secured purchaseorder for $6.5 million in dialysis products of which $3.2 million is
      reflected in first half 2005 results.
• Initiated $2.5 million in annualized new supply business in the Southeast.
• Beganoperations in new manufacturing plant in South Carolina.

Mr. Robert L. Chioini, Chairman and Chief Executive Officer of Rockwell Medical Technologies, Inc. stated, “We are pleased with our strong sales growth and second quarter results. In March, we added a new production facility in South Carolina which increased our overall capacity but also increased our expenses. In addition, we incurred increased operating expenses as we transitioned business between plants and added personnel and equipment to handle new business opportunities. We expect this investment to provide us with the infrastructure to support additional business in the future.”

Rockwell will be hosting a conference call to review its second quarter results on Wednesday, August 10, 2005 at 11:00 am EDT. Investors are encouraged to call in five minutes in advance of the call at 888-896-0862 or may listen on the web at: http://orion.calleci.com/servlet/estreamgetevent?id=5764&folder=default using Windows Media Player. See rockwellmed.com for more details and playback options.

Rockwell Medical Technologies, Inc. is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products that improve the quality of care for dialysis patients. Dialysis is a process that duplicates kidney function for those patients whose kidneys have failed to work properly and suffer from chronic kidney failure, a condition also known as end stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the proprietary Dri-Sate® Dry Acid Mixing System, RenalPure™ Liquid Acid, RenalPure™ Powder Bicarbonate, SteriLyte® Liquid Bicarbonate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release with respect to Rockwell's business and operations, including the statements regarding the Company's anticipated sales revenue and gross profit margins constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors, failure to obtain FDA approval, and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., announced today that it will hold a conference call on Wednesday, August 10, 2005 at 11:00AM EST to discuss its second quarter 2005 results. The Company intends to release its results before the market opens on the same date. Rob Chioini, Chairman and CEO, and Thomas Klema, CFO, will be hosting the call to review Rockwell's results and answer questions from investors.

The call will be held on:

Wednesday, August 10, 2005
Starting Time 11:00AM Eastern Time
Dial in Number: 888-896-0862

When calling in please refer to the Rockwell Medical Technologies, Second Quarter Conference Call and provide the operator with your name and company affiliation.

Investors who prefer to participate using the internet may access the following link for Real Player:
http://orion.calleci.com/servlet/estreamgetevent?id=5762&folder=default

Or for Windows Media Player:
http://orion.calleci.com/servlet/estreamgetevent?id=5764&folder=default

International Investors may dial in directly on 973-935-8597

Investors who are unable to listen to the Rockwell earnings conference call will be able to access a replay via our web site at www.rockwellmed.com. There will be no telephone replay.

We appreciate your interest in Rockwell

WIXOM, Mich. -- Rockwell Medical Technologies, Inc. a leading, innovative hemodialysis products manufacturer in the healthcare sector, reported its first quarter results today. Sales were up 30.4% over the first quarter last year. Net income of $109,215 increased $29,000 or 36% over the first quarter 2004. Earnings per Share for the quarter was $.01.

HIGHLIGHTS:

First Quarter 2005

• Record quarterly revenues of $5,619,508.
• Salesrevenues increased 30.4% over the first quarter of 2004.
• Salesrevenue was up 17.6% sequentially over the fourth quarter of 2004.
• Concentrateproduct line revenue increased 40% over the first quarter of 2004.
• Dri-Sate®Dry Acid Concentrate unit volume increased 50% over the first quarter of 2004.
• Liquid acidconcentrate gallons increased by 70% over first quarter of 2004.
• NetIncome was $109,215
• Earningsper Share was $.01
• Substantialmarket share gain in the Southeast region.
• Newmanufacturing plant in Southeast region began operations in March.
• Secureda $6,500,000 purchase order for dialysis products.

Mr. Robert L. Chioini, Chairman, CEO, and President of Rockwell Medical Technologies, Inc. stated, “We are pleased with our first quarter sales results and we expect to continue to experience revenue growth in the second quarter. We developed a significant amount of new business during the last year. We also secured supply agreements with several providers located in the Southeastern U.S. To service Southeastern U.S. providers we established a manufacturing and distribution facility in the South in March. We also secured a $6,500,000 purchase order which should result in a substantial sales increase for the Company for calendar year 2005.”

Mr. Chioini also stated, “We incurred higher than usual distribution costs over the last six months due to our penetration of the Southeast market prior to establishing our plant which was a major contributing factor to the decline in our gross profit margins. Our gross profit margins declined over the last six months as we built our book of business to where we could justify a self funding facility in the Southeast. We achieved that objective when we opened our new manufacturing facility in March. We expect our gross profit margins to improve as a result of our regional presence going forward.”

Rockwell will be hosting a conference call to review its first quarter results on Thursday, May 12, 2005 at 11:00 am EDT. Investors are encouraged to call in five minutes in advance of the call at 888-896-0862 or may listen on the web at: http://orion.calleci.com/servlet/estreamgetevent?id=5423&folder=default using Windows Media Player. See rockwelllmed.com for more details and playback options.

Rockwell Medical Technologies, Inc. is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products that improve the quality of care for dialysis patients. Dialysis is a process that duplicates kidney function for those patients whose kidneys have failed to work properly and suffer from chronic kidney failure, a condition also known as end stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the proprietary Dri-Sate® Dry Acid Mixing System, RenalPure™ Liquid Acid, RenalPure™ Powder Bicarbonate, SteriLyte® Liquid Bicarbonate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release with respect to Rockwell's business and operations, including the statements regarding the Company's anticipated sales revenue and gross profit margins constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors, failure to obtain FDA approval, and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., announced today that it will hold a conference call on Thursday, May 12, 2005 at 11:00AM EST to discuss its first quarter 2005 results. The Company intends to release its results before the market opens on the same date. Rob Chioini, Chairman and CEO, and Thomas Klema, CFO, will be hosting the call to review Rockwell's results and answer questions from investors.

The call will be held on:

Thursday, May 12, 2005
Starting Time 11:00AM Eastern Time
Dial in Number: 888-896-0862

When calling in please refer to the Rockwell Medical Technologies, First Quarter Conference Call and provide the operator with your name and company affiliation.

Investors who prefer to participate using the internet may access the following link for Real Player:
http://orion.calleci.com/servlet/estreamgetevent?id=5421&folder=default

Or for Windows Media Player:
http://orion.calleci.com/servlet/estreamgetevent?id=5422&folder=default

International Investors may dial in directly on 973-935-8597

Investors who are unable to listen to the Rockwell earnings conference call will be able to access a replay via our web site at www.rockwellmed.com. There will be no telephone replay.

We appreciate your interest in Rockwell

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative dialysis products manufacturer serving the healthcare industry reported today that it has secured $6,500,000 in business with a new customer. The Company fulfilled approximately $600,000 of the business during the first quarter of 2005 and has since secured the purchase order for the entire $6,500,000 worth of business. The Company anticipates fulfilling the majority of the purchase order during the second quarter of 2005.

Mr. Robert L. Chioini, Chairman, CEO and President of Rockwell stated, “We expect this order to be favorable to our sales in the second quarter and we are currently working to secure more of this business on an ongoing basis.”

Earlier this year, Rockwell reported that it had secured multiple supply contracts aggregating $2,500,000 in the Southeast region. Rockwell subsequently announced a new facility in the Southeast which commenced production and distribution operations during March of this year. Rockwell reported revenue growth of 20% in 2004 with sales of $18,000,000.

Rockwell Medical Technologies, Inc. is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products that improve the quality of care for dialysis patients. Dialysis is a process that duplicates kidney function for those patients whose kidneys have failed to work properly and suffer from chronic kidney failure, a condition also known as end stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased approximately 6% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the proprietary Dri-Sate® Dry Acid Mixing System, RenalPure™ Liquid Acid, SteriLyte™ Liquid Bicarbonate, RenalPure® Powder Bicarbonate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release with respect to Rockwell's anticipated sales revenue constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, any breach of a contract by a major customer, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading and innovative hemodialysis concentrate manufacturer in the fast growing dialysis market, announced today that it has signed a $2.75 million revolving credit loan facility with Standard Federal Bank, a subsidiary of ABN AMRO.

Under the terms of the loan agreement, dated March 29, 2005, the credit facility has a limit of $2,750,000. The loan facility expires March 31, 2006 and is secured by the Company's accounts receivable, inventory and certain other assets.

Mr. Thomas E. Klema, Vice President and Chief Financial Officer of Rockwell stated “We are pleased to announce our new credit facility which provides us with increased borrowing capacity at more favorable rates. This credit line should provide us with the working capital resources we need to support our growth. Standard Federal Bank provides us with a strong financial partner who understands the dynamic nature of an emerging growth company like Rockwell.”

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc. a leading, innovative hemodialysis products manufacturer in the healthcare sector, reported its fourth quarter and full year 2004 results today with 2004 Earnings per Share improving by $.02 per share. Highlights:

Fourth Quarter 2004

• Record quarterly revenues of $4,780,070.
• Salesrevenues increased 15.4% over the fourth quarter of 2003.
• Salesrevenue was up 6.8% sequentially over the third quarter of 2004.
• Concentrateproduct line revenue increased 26% over the fourth quarter of 2003.
• Dri-Sate®Dry Acid Concentrate unit volume increased 25% over the fourth quarter of 2003.
• OperatingIncome was $70,980; net income was $11,404.
• Substantialmarket share gain in the Southeast region.

• Sales revenue increased 20% in 2004 over 2003.
• Concentraterevenue increased 30%; driven by broad growth across all product lines.
• Dri-Sate®Dry Acid Concentrate unit volumes increased 38% over last year.
• Operatingincome of $409,000 more than doubled.
• Netincome improved by $207,000 over 2003.
• Earningsper share was $.02 in 2004; an improvement of $.02 per share over 2003.

Mr. Robert L. Chioini, Chairman, CEO, and President of Rockwell Medical Technologies, Inc. stated, “We are pleased with our results for 2004. We substantially grew our business, we achieved our second year of profitable operations and we expanded our geographic scope of business in the fourth quarter with significant penetration into the Southeast.” Mr. Chioini also stated, "We made substantial investments in iron product development and market share expansion in the fourth quarter. These investments were essential for our future development. Our overall iron development spending increased by $50,000 over the third quarter level, with more than $100,000 spent in total for the fourth quarter. As a result of this investment, coupled with an increase in new business outside of our traditional distribution footprint, we incurred higher than normal operating and distribution expenses. Although these growth initiatives reduced our earnings in the fourth quarter we are excited about our prospects for 2005.”

Rockwell is seeking FDA approval for a proprietary drug product containing Ferric Pyrophosphate (FePPi) to be delivered by its dialysis concentrates. It believes FePPi, delivered via dialysate, is a superior iron compound and delivery method for the treatment of anemia in dialysis patients as compared to the current intravenous (IV) iron drugs used today. The Company is seeking FDA approval of the product, which it intends to market. The Company believes that the current market for IV iron is $300 million in the United States and more than $500 million globally. As compared to IV iron administration, the Company believes that administering the drug through its dialysate is a safer and more effective method for maintaining iron balance in dialysis patients, while at the same time eliminating the associated nursing and pharmaceutical IV iron administration costs. Rockwell holds the exclusive rights to the patents which cover the pharmaceutical composition, methods of use and delivery of iron to be administered via dialysate to both hemodialysis and peritoneal dialysis patients.

Rockwell will be hosting a conference call to review its fourth quarter and year end results on Thursday, February 24, 2005 at 11:00 am EST. Investors are encouraged to call in 5-10 minutes in advance of the call at 888-896-0862 or may listen on the web at: http://orion.calleci.com/servlet/estreamgetevent?id=4813&folder=default using Windows Media Player. See rockwelllmed.com for more details and playback options.

Rockwell Medical Technologies, Inc. is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products that improve the quality of care for dialysis patients. Dialysis is a process that duplicates kidney function for those patients whose kidneys have failed to work properly and suffer from chronic kidney failure, a condition also known as end stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the proprietary Dri-Sate® Dry Acid Mixing System, RenalPure™ Liquid Acid, RenalPure™ Powder Bicarbonate, SteriLyte® Liquid Bicarbonate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release with respect to Rockwell's business and operations, including the statements regarding the Company's proprietary dialysate iron-therapy product, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors, failure to obtain FDA approval, and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, announced today that it has leased a turn-key concentrate manufacturing facility in South Carolina. This is the Company's third regional production facility which now includes the Midwest (MI), Southwest (TX) and Southeast (SC).

Located in Hodges, South Carolina the 61,000 square foot facility is expected to be fully operational by the end of the first quarter and will service both existing and new customers in the region. The Company anticipates shifting existing Southeast business currently serviced from its Michigan and Texas plants to the South Carolina plant. The Company believes a Southeast facility will reduce distribution costs in the Southeast region. This leased manufacturing facility provides the Company with an interim Southeastern presence while it evaluates the potential to establish a long-term Southeastern regional facility.

In the fourth quarter of 2004, the Company added substantial business in the Southeastern region. In addition, on February 15, 2005, Rockwell announced that it had signed multiple concentrate supply contracts in the Southeastern region. In the aggregate, the new business in the Southeast calls for Rockwell to supply dialysis concentrate to approximately 12,000 patients in 160 clinics.

Mr. Robert L. Chioini, Chairman, CEO and President of Rockwell, stated, “Based on the substantial growth we have experienced in the Southeast during the fourth quarter of 2004 and this first quarter of 2005, coupled with our strategic expansion initiative, we have added production and distribution resources to address that growth. We recognize the need to establish a presence in the Southeast and now we are well positioned to service those customer's needs as well as gain a greater presence in the dialysis provider market in that region.”

Rockwell Medical Technologies, Inc. is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products that improve the quality of care for dialysis patients. Dialysis is a process that duplicates kidney function for those patients whose kidneys have failed to work properly and suffer from chronic kidney failure, a condition also known as end stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the proprietary Dri-Sate® Dry Acid Mixing System, RenalPure™ Liquid Acid, RenalPure™ Powder Bicarbonate, SteriLyte® Liquid Bicarbonate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release with respect to Rockwell's anticipated sales revenue constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, announced today that it has signed a series of supply contracts with several U.S. hemodialysis providers. The new business strengthens the Company's geographic presence in the South-Atlantic and Mid-Atlantic regions.

Rockwell has secured separate concentrate supply contracts with Independent Dialysis Foundation (IDF), Health Systems Management (HSM), Central Florida Kidney Centers, Inc. (CFKC), Dialysis Clinics Inc. - Southeast Region, (DCI) and Dialysis Corporation of America, Inc. (Nasdaq: DCAI). In aggregate, the contracts call for Rockwell to supply dialysis concentrate to approximately 6000 patients in 80 clinics. The supply contracts are expected to generate approximately $2.5 million in annual sales revenue for Rockwell.

Mr. Robert L. Chioini, Chairman, CEO and President of Rockwell stated, “We are pleased to have secured concentrate business with each of these prominent dialysis providers. This new business significantly strengthens our market presence in the Southeast. We anticipate realizing the full revenue impact in the second quarter of this year.”

Rockwell Medical Technologies, Inc. is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products that improve the quality of care for dialysis patients. Dialysis is a process that duplicates kidney function for those patients whose kidneys have failed to work properly and suffer from chronic kidney failure, a condition also known as end stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the proprietary Dri-Sate® Dry Acid Mixing System, RenalPure™ Liquid Acid, RenalPure™ Powder Bicarbonate, SteriLyte® Liquid Bicarbonate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release with respect to Rockwell's anticipated sales revenue constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc.announced today that it will hold a conference call on Thursday, February 24, 2005 at 11:00AM EDT to discuss 2004 fourth quarter and year end results. The Company intends to release its results before the market opens on the same date. Rob Chioini, Chairman and CEO, and Thomas Klema, CFO, will be hosting the call to review Rockwell's results and answer questions from investors.

The call will be held on:

Thursday, February 24, 2005
Starting Time 11:00AM Eastern Time
Dial in Number: 888-896-0862

When calling in please refer to the Rockwell Medical Technologies, Q4 2004 Conference Call and provide the operator with your name and company affiliation.

Investors who prefer to participate using the internet may access the following link for Real Player:
http://orion.calleci.com/servlet/estreamgetevent?id=4811&folder=default

Or for Windows Media Player:
http://orion.calleci.com/servlet/estreamgetevent?id=4813&folder=default

International Investors may dial in directly on 973-935-8597

Investors who are unable to listen to the Rockwell earnings conference call will be able to access a replay via our web site at www.rockwellmed.com. There will be no telephone replay.

We appreciate your interest in Rockwell